{"title":"Coagulation Disorder’s in SARS-CoV-2 Patients","authors":"Akram Aghaamini Fashami, Mahtab Sayadi, Ebrahim Miri Moghaddam","doi":"10.5812/zjrms-121045","DOIUrl":null,"url":null,"abstract":"Context: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease of 2019 (COVID-19). Pulmonary manifestations have been identified as the common symptom, and patients present a wide range of hematologic changes depending on the flow of the diseases. The interpretation and treatment of hematological complications in COVID-19 patients are very challenging. There are limited guidelines thus far due to the novelty of the disease. Evidence Acquisition: This review summarizes the hematological findings (platelet and coagulation/fibrinolytic) in COVID-19 patients and discusses possible mechanisms for their changes. Results: The results showed that the common findings were thrombocytopenia, elevated D-dimer levels, and prolonged prothrombin time (PT) and partial thromboplastin time (PTT) in severe patients. Conclusions: Attention to hematological changes may be helpful biomarkers in diagnosing and determining patients needing intensive care, as well as monitoring the treatment process and treatment effects on COVID-19 patients.","PeriodicalId":292747,"journal":{"name":"Zahedan Journal of Research in Medical Sciences","volume":"45 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Zahedan Journal of Research in Medical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5812/zjrms-121045","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Context: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease of 2019 (COVID-19). Pulmonary manifestations have been identified as the common symptom, and patients present a wide range of hematologic changes depending on the flow of the diseases. The interpretation and treatment of hematological complications in COVID-19 patients are very challenging. There are limited guidelines thus far due to the novelty of the disease. Evidence Acquisition: This review summarizes the hematological findings (platelet and coagulation/fibrinolytic) in COVID-19 patients and discusses possible mechanisms for their changes. Results: The results showed that the common findings were thrombocytopenia, elevated D-dimer levels, and prolonged prothrombin time (PT) and partial thromboplastin time (PTT) in severe patients. Conclusions: Attention to hematological changes may be helpful biomarkers in diagnosing and determining patients needing intensive care, as well as monitoring the treatment process and treatment effects on COVID-19 patients.